Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
about
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsPharmacokinetic drug interaction profiles of proton pump inhibitors: an updateSignificant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virusRationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers.Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.Acid suppressive therapy and the effects on protease inhibitors.Atazanavir: simplicity and convenience in different scenarios.Drug interactions between proton pump inhibitors and antiretroviral drugs.Interactions between protease inhibitors and acid-reducing agents: a systematic review.A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.Atazanavir: its role in HIV treatmentRilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.Clinical pharmacology, efficacy and safety of atazanavir: a review.Clinically significant drug interactions with antacids: an update.Consequences of gastrointestinal surgery on drug absorption.A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine ProductsAdverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method.Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease.A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.The influence of race and comorbidity on the timely initiation of antiretroviral therapy among older persons living with HIV/AIDS.Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects.
P2860
Q27004032-400682B2-7943-46DB-A1B7-8F527AEC7A20Q27022254-F4CD91BB-EEDE-464B-A5AA-5727B9BF0FBEQ33155841-007624D4-121C-403F-82F4-C30CCF2D2985Q34966486-1F8D8579-E040-4F1F-B0B8-90112B74E54DQ35755917-DD060124-BFDE-45C5-8E74-F88A319F6293Q36591913-F667A59B-E8E4-49B6-BD75-0303CCFD0FE6Q36640626-494A2192-CAB2-4BCF-B107-67D9AD1502FDQ36765802-4BFFE220-F92E-46DA-98C2-DC8EA05C5685Q36788409-A7E54CB6-23C6-451B-B1AB-C346F2104BE3Q36895942-6A3ECD98-392E-4F38-B4F3-5E073C92F3C6Q37038172-5A0BC241-DBEB-4D34-B6E0-8B85232DDEFAQ37249418-A0ABEB4B-BAEE-416C-A482-B87F4E176C10Q37528451-5B87C5D8-F939-43E8-9996-EA7F42EF645BQ37622972-B15B18EA-6F2D-49E2-8DB0-FCC4569631D3Q37937722-0DAD5C5E-0D2D-4EA2-8CA5-C7B06CF4C18AQ38120133-3AC9181D-85D2-4E29-AD21-D4E55CB6189CQ38513275-A84A3A38-6F87-474F-A56A-9932353A8994Q38658675-11A6DA69-977B-43D1-8216-C178279D1849Q41404243-C4E79204-4603-4AC6-8CF0-3C250329AB2AQ46384364-164D6D58-F977-4851-A575-CFD15B45175EQ51337867-FEFF5AEB-E2A1-48B2-A9AF-74635CD237BAQ53829397-8CDFF305-52A0-4020-9458-93BF09071EEAQ54328018-BB8A3183-0DC3-454A-93AA-FD07E9C2A618
P2860
Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Inhibition of atazanavir oral ...... ression in healthy volunteers.
@en
Inhibition of atazanavir oral ...... ression in healthy volunteers.
@nl
type
label
Inhibition of atazanavir oral ...... ression in healthy volunteers.
@en
Inhibition of atazanavir oral ...... ression in healthy volunteers.
@nl
prefLabel
Inhibition of atazanavir oral ...... ression in healthy volunteers.
@en
Inhibition of atazanavir oral ...... ression in healthy volunteers.
@nl
P2093
P2860
P356
P1433
P1476
Inhibition of atazanavir oral ...... ression in healthy volunteers.
@en
P2093
Abayomi B Ogundele
Charles S Berenson
Desiree L Tomilo
Edward Bednarczyk
Ellana Eberhardt
Gene D Morse
Patrick F Smith
Robin Difrancesco
P2860
P304
P356
10.1592/PHCO.26.3.341
P407
P577
2006-03-01T00:00:00Z